Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 9, 2010, Mallinckrodt, Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

DrugSchedule
Tetrahydrocannabinols (7370)I
Codeine-N-oxide (9053)I
Dihydromorphine (9145)I
Difenoxin (9168)I
Morphine-N-oxide (9307)I
Normorphine (9313)I
Norlevorphanol (9634)I
Amphetamine (1100)II
Methamphetamine (1105)II
Methylphenidate (1724)II
Nabilone (7379)II
Codeine (9050)II
Diprenorphine (9058)II
Etorphine HCl (9059)II
Start Printed Page 14690
Dihydrocodeine (9120)II
Oxycodone (9143)II
Hydromorphone (9150)II
Diphenoxylate (9170)II
Ecgonine (9180)II
Hydrocodone (9193)II
Levorphanol (9220)II
Meperidine (9230)II
Methadone (9250)II
Methadone intermediate (9254)II
Metopon (9260)II
Dextropropoxyphene, bulk (9273)II
Morphine (9300)II
Oripavine (9330)II
Thebaine (9333)II
Opium extracts (9610)II
Opium fluid extract (9620)II
Opium tincture (9630)II
Opium, powdered (9639)II
Opium, granulated (9640)II
Levo-alphacetylmethadol (9648)II
Oxymorphone (9652)II
Noroxymorphone (9668)II
Alfentanil (9737)II
Remifentanil (9739)II
Sufentanil (9740)II
Fentanyl (9801)II

The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 16, 2011.

Start Signature

Dated: March 9, 2011.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. 2011-6157 Filed 3-16-11; 8:45 am]

BILLING CODE 4410-09-P